Porcine xenografts for human organ transplantation
- Summary
- Xenotransplantation, or transplantation of animal-derived organs or tissues, is a potential solution to the worldwide shortage of donor organs. In particular, the pig is regarded as a favorable species for clinical transplantation into humans because of greater availability, similarity in organ size, and reduced risk of infections. However, hyperacute rejection of xenografts, in which the foreign donor tissue is destroyed by the recipient’s immune response, remains a critical barrier to xenotransplantation. This technology describes transgenic pigs that lack the expression of α(1-3)-galactosyltransferase (GalT), an enzyme that produces one of the primary antigens that trigger hyperacute rejection. By inhibiting the production of this epitope, this technology potentially enables the transplantation of porcine tissue into humans without the risk of hyperacute rejection.
- Technology Benefits
- Decreased immunologic response and risk of rejection following xenotransplantationDecreased need for immunosuppressive therapy post-transplantationPatent Information:Patent Issued (US 6,153,428)Patent Issued (US 6,413,769)Tech Ventures Reference: IR Proxy73
- Technology Application
- Xenografts for patients needing organ and tissue transplantsCells and tissue for xenotransplantation researchTransplant models for surgical training
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Jerry KokoshkaColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- Proxy73
- *Principal Investigator
-
- Country/Region
- USA
For more information, please click Here
